FI972775A0 - Uudet kvinuklidiinijohdokset ja näiden lääkinnälliset seokset - Google Patents

Uudet kvinuklidiinijohdokset ja näiden lääkinnälliset seokset

Info

Publication number
FI972775A0
FI972775A0 FI972775A FI972775A FI972775A0 FI 972775 A0 FI972775 A0 FI 972775A0 FI 972775 A FI972775 A FI 972775A FI 972775 A FI972775 A FI 972775A FI 972775 A0 FI972775 A0 FI 972775A0
Authority
FI
Finland
Prior art keywords
quinuclidine derivatives
diseases
medicinal mixtures
new quinuclidine
medicinal
Prior art date
Application number
FI972775A
Other languages
English (en)
Swedish (sv)
Other versions
FI115631B (fi
FI972775A7 (fi
Inventor
Makoto Takeuchi
Ryo Naito
Masahiko Hayakawa
Yoshinori Okamoto
Yasuhiro Yonetoku
Ken Ikeda
Yasuo Isomura
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI972775(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of FI972775A0 publication Critical patent/FI972775A0/fi
Publication of FI972775A7 publication Critical patent/FI972775A7/fi
Application granted granted Critical
Publication of FI115631B publication Critical patent/FI115631B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Tea And Coffee (AREA)
FI972775A 1994-12-28 1997-06-27 Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus FI115631B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (en) 1994-12-28 1995-12-27 Novel quinuclidine derivatives and medicinal composition thereof
JP9502713 1995-12-27

Publications (3)

Publication Number Publication Date
FI972775A0 true FI972775A0 (fi) 1997-06-27
FI972775A7 FI972775A7 (fi) 1997-08-22
FI115631B FI115631B (fi) 2005-06-15

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972775A FI115631B (fi) 1994-12-28 1997-06-27 Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus

Country Status (24)

Country Link
US (2) US6017927A (fi)
EP (1) EP0801067B1 (fi)
JP (1) JP3014457B2 (fi)
KR (1) KR100386487B1 (fi)
CN (1) CN1045601C (fi)
AT (1) ATE233761T1 (fi)
AU (1) AU695616B2 (fi)
CA (1) CA2208839C (fi)
DE (2) DE122004000048I2 (fi)
DK (1) DK0801067T3 (fi)
ES (1) ES2193208T3 (fi)
FI (1) FI115631B (fi)
FR (1) FR04C0032I2 (fi)
HU (1) HU223778B1 (fi)
LU (1) LU91133I9 (fi)
MX (1) MX9704880A (fi)
NL (1) NL300141I2 (fi)
NO (4) NO2005012I1 (fi)
NZ (1) NZ298144A (fi)
PL (1) PL182344B1 (fi)
PT (1) PT801067E (fi)
RU (1) RU2143432C1 (fi)
TW (1) TW305842B (fi)
WO (1) WO1996020194A1 (fi)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
MXPA03000141A (es) * 2000-06-27 2003-05-27 S A L V A T Lab Sa Carbamatos derivados de arilalquilaminas.
SK8002003A3 (en) 2000-12-22 2004-05-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
EP1353919B1 (en) 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
JP4174673B2 (ja) * 2001-07-10 2008-11-05 アステラス製薬株式会社 間質性膀胱炎治療用医薬組成物
KR100944580B1 (ko) * 2001-12-20 2010-02-25 치에시 파마슈티시 에스.피.아. 1-알킬-1-아조니아비시클로[2.2.2]옥탄 카르바메이트유도체 및 이의 무스카린 수용체 길항제로서의 용도
BR0311414A (pt) * 2002-06-07 2005-03-15 Yamanouchi Pharma Co Ltd Agente terapêutico para uma bexiga hiperativa
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
BR0215801A (pt) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
ATE396969T1 (de) 2002-07-31 2008-06-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen
US7410993B2 (en) 2002-08-09 2008-08-12 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists
US7288562B2 (en) 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
BR0315784A (pt) * 2002-10-29 2005-09-20 Pharmacia & Upjohn Co Llc Compostos de amÈnio quaternário
WO2004052857A1 (en) 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
WO2004058168A2 (en) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
US7465751B2 (en) 2002-12-23 2008-12-16 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
ATE386738T1 (de) * 2002-12-23 2008-03-15 Ranbaxy Lab Ltd Flavaxat-derivate als muscarin-rezeptor antagonisten
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
DE60313898T2 (de) 2003-04-10 2008-01-17 Ranbaxy Laboratories, Ltd. Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
EP1615887A1 (en) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089900A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
WO2005075474A1 (ja) * 2004-02-09 2005-08-18 Astellas Pharma Inc. コハク酸ソリフェナシン含有組成物
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
WO2005087231A1 (ja) * 2004-03-16 2005-09-22 Astellas Pharma Inc. ソリフェナシン含有組成物
JPWO2005087231A1 (ja) * 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
ZA200608614B (en) * 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
KR101836467B1 (ko) * 2004-03-25 2018-03-08 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
WO2006035280A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
ES2342675T3 (es) * 2004-12-22 2010-07-12 Memory Pharmaceuticals Corporation Ligandos del receptor alfa-7 nicotinico contra enfermedades relacionadas con el snc.
ES2387571T3 (es) * 2004-12-27 2012-09-26 Astellas Pharma Inc. Composición farmacéutica granulada estable de solifenacina o de su sal
AU2005320672B2 (en) * 2004-12-27 2011-01-06 Astellas Pharma Inc. Stable particulate pharmaceutical composition of solifenacin or salt thereof
WO2006090759A1 (ja) * 2005-02-25 2006-08-31 Astellas Pharma Inc. ソリフェナシン含有医薬
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
US20080255188A1 (en) * 2005-07-11 2008-10-16 Naresh Kumar Muscarinic Receptor Antagonists
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2007076116A2 (en) * 2005-12-21 2007-07-05 Teva Pharmaceutical Industries Ltd. Intermediates for preparing solifenacin
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
US20090326230A1 (en) * 2006-07-19 2009-12-31 Dr. Reddy's Laboratories Ltd. Process for preparing solifenacin and its salts
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2043639A2 (en) * 2006-07-24 2009-04-08 Teva Pharmaceutical Industries Ltd. Processes for preparing polymorphic forms of solifenacin succinate
WO2008019057A2 (en) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd. Polymorphs of solifenacin intermediate
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008062282A2 (en) * 2006-11-22 2008-05-29 Medichem S.A. An improved process for the synthesis of solifenacin
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
AR066206A1 (es) * 2007-03-30 2009-08-05 Medichem Sa Proceso para la sintesis de solifenacina
EP2146693A2 (en) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
JP2009538362A (ja) * 2007-07-13 2009-11-05 テバ ファーマシューティカル インダストリーズ リミティド ソリフェナシンの調製方法
JPWO2009013846A1 (ja) 2007-07-20 2010-10-07 アステラス製薬株式会社 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
SI2216021T1 (sl) * 2007-11-02 2013-01-31 Astellas Pharma Inc. Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
JP2011505416A (ja) * 2007-12-04 2011-02-24 カディラ ヘルスケア リミティド 化学的及びキラル的に純粋なソリフェナシン塩基及びその塩を調製する方法
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CA2718411C (en) 2008-03-27 2016-02-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
PL385265A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
EP3067353B1 (en) 2008-07-29 2017-11-22 KRKA, D.D., Novo Mesto A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
HUE029638T2 (en) * 2009-02-04 2017-03-28 Astellas Pharma Inc Pharmaceutical preparation for oral administration
EP2406257B1 (en) 2009-03-09 2019-08-07 Megafine Pharma (P) Ltd. A new method for the preparation of solifenacin and new intermediate thereof
JP4816828B2 (ja) * 2009-03-30 2011-11-16 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (en) 2009-09-25 2011-04-28 Cadila Healthcare Limited Processes for the preparation of solifenacin or a salt thereof
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
WO2011125763A1 (ja) 2010-03-31 2011-10-13 小野薬品工業株式会社 手足症候群の予防および／または治療剤
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
JP5831449B2 (ja) 2010-05-19 2015-12-09 アステラス製薬株式会社 ソリフェナシン含有医薬組成物
WO2012001481A1 (en) 2010-06-28 2012-01-05 Aurobindo Pharma Limited Novel process for the preparation of solifenacin succinate
US8765785B2 (en) 2010-07-05 2014-07-01 Crystal Pharma, S.A.U. Solifenacin salts
EP2638039A1 (de) 2010-11-11 2013-09-18 Hexal AG Kristallines solifenacin-succinat
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CA2835277A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
JP2014520126A (ja) 2011-06-22 2014-08-21 イソケム ソリフェナシンおよびその塩の製造方法
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
EP2867210A1 (en) * 2012-07-02 2015-05-06 Pharmathen S.A. A process for the preparation of solifenacin or a salt thereof
CA2883270A1 (en) 2012-08-31 2014-03-06 Astellas Pharma Inc. Orally administered medical composition
EP2892514A4 (en) 2012-09-05 2016-04-13 Chase Pharmaceuticals Corp Neurotropic Anticholinergic Composition and Method
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
WO2014086927A1 (en) * 2012-12-06 2014-06-12 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
BR112016000629B1 (pt) * 2013-07-13 2023-10-31 Beijing Showby Pharmaceutical Co., Ltd. Compostos de quinina e isômeros ópticos, método de preparação e utilização médica dos mesmos
CA2944714C (en) 2014-05-06 2023-05-16 Anthony G. Visco Methods of treating or preventing preterm labor
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
TW201927783A (zh) * 2017-12-12 2019-07-16 美商阿爾庫達醫療公司 顆粒體蛋白前體調節劑及其使用方法
CN112368282B (zh) 2018-05-08 2023-10-13 日本新药株式会社 氮杂苯并咪唑化合物和医药
AR119149A1 (es) 2019-06-12 2021-11-24 Arkuda Therapeutics Derivados de isoquinolina como moduladores de la progranulina
AU2020384041A1 (en) 2019-11-13 2022-06-09 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053451T3 (es) * 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
ATE339121T1 (de) * 2002-11-27 2006-10-15 Selmac S R L Vorrichtung zum positionieren und spannen geformter teile und damit ausgerüstete maschine

Also Published As

Publication number Publication date
DE122004000048I1 (de) 2005-04-21
DE122004000048I2 (de) 2006-02-02
EP0801067A1 (en) 1997-10-15
ES2193208T3 (es) 2003-11-01
JPH09508401A (ja) 1997-08-26
US6174896B1 (en) 2001-01-16
DE69529844T2 (de) 2004-03-04
PL321019A1 (en) 1997-11-24
KR987000303A (ko) 1998-03-30
US6017927A (en) 2000-01-25
DE69529844D1 (de) 2003-04-10
FR04C0032I1 (fi) 2005-02-11
NO973027L (no) 1997-08-28
DK0801067T3 (da) 2003-06-30
AU4355396A (en) 1996-07-19
NO2017055I1 (no) 2017-11-06
PT801067E (pt) 2003-07-31
HU223778B1 (hu) 2005-01-28
CN1171109A (zh) 1998-01-21
NZ298144A (en) 1998-04-27
LU91133I9 (en) 2018-08-01
NO2017055I2 (no) 2017-11-06
FI115631B (fi) 2005-06-15
NL300141I1 (nl) 2004-04-01
NO2005016I2 (no) 2008-02-11
KR100386487B1 (ko) 2003-09-26
HUT77006A (hu) 1998-03-02
LU91133I2 (fr) 2005-03-29
NO973027D0 (no) 1997-06-27
EP0801067B1 (en) 2003-03-05
NO2005012I1 (no) 2005-06-06
EP0801067A4 (en) 1998-03-11
CA2208839A1 (en) 1996-07-04
TW305842B (fi) 1997-05-21
WO1996020194A1 (en) 1996-07-04
AU695616B2 (en) 1998-08-20
CN1045601C (zh) 1999-10-13
FR04C0032I2 (fr) 2005-10-21
JP3014457B2 (ja) 2000-02-28
RU2143432C1 (ru) 1999-12-27
NO2005016I1 (no) 2005-08-29
ATE233761T1 (de) 2003-03-15
MX9704880A (es) 1997-10-31
NO318026B1 (no) 2005-01-24
CA2208839C (en) 2006-01-31
FI972775A7 (fi) 1997-08-22
PL182344B1 (pl) 2001-12-31
NL300141I2 (nl) 2004-04-01

Similar Documents

Publication Publication Date Title
FI972775A0 (fi) Uudet kvinuklidiinijohdokset ja näiden lääkinnälliset seokset
NO180166C (no) Pyrrolidin- og tiazolidinderivater samt medikamenter inneholdende forbindelsene
ATE109484T1 (de) Thienopyridin -derivative und diese enthaltende arzneimittel.
HUT59139A (en) Process for producing tricyclic compounds and antimicrobial pharmaceutical compositions comprising same
DE69617226D1 (de) Piperidinderivate.
DE69121259D1 (de) Beta-Lactam-Verbindungen und ihre Herstellung
ATE131478T1 (de) 4-((2-benzothiazolyl)methylamino>-alpha-(3,4- difluorphenoxy)methyl-1-piperidenethanol
NO910904L (no) Fremgangsmaate for fremstilling av en substituert aminforbindelse.
ATE209197T1 (de) Imidazolidinon-derivate, deren säure- additionssalze und mittel gegen senile demenz
DK0566288T3 (da) Flavon-derivater
DK0580503T3 (da) Aminoalkylchromoner, fremgangsmåde til fremstilling heraf samt midler indeholdende disse
DE69706012D1 (de) N-Acylpiperazinderivat, antibakterielle und gegen Geschwüre wirksame Medikamente
FI933928A0 (fi) Heteroarenylpiperaziner, foerfarande foer framstaellning av dessa och anvaendning som laekemedel

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115631

Country of ref document: FI

SPCF Supplementary protection certificate application filed
PC Transfer of assignment of patent

Owner name: ASTELLAS PHARMA INC.

Free format text: ASTELLAS PHARMA INC.

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 272

Extension date: 20181216

MA Patent expired
SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20050024

SPCX Supplementary protection certificate: correction

Spc suppl protection certif: 272

Extension date: 20190622